CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02731729
NCT02731729Phase 2Completed
CompareCT.gov

A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Parker Institute for Cancer Immunotherapy·interventional·Posted Apr 7, 2016·Updated Dec 23, 2022

In Brief

A Phase 2 clinical trial evaluating ipilimumab and nivolumab for Melanoma. Completed, enrolled 20 participants across 7 sites.

Detailed Summary

The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 7, 2016
Enrollment StartJun 21, 2016
Primary CompletionAug 27, 2018
Study CompletionFeb 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.2 years ago

Interventions

ipilimumabdrug

nivolumabdrug